Market Access News | pharmaphorum

News

Roche's blockbuster breast cancer drug Herceptin

Sandoz strikes deal with EirGenix for Herceptin biosimilar

Sandoz has struck a deal with Taiwan-based EirGenix to market a late-stage biosimilar of Roche’s breast cancer blockbuster Herceptin.

News

NHS trumpets Hep C deal, quietly drops 2025 elimination targ...

NHS England has announced a deal with AbbVie, Gilead, and Merck, Sharpe and Dohme (MSD) that aims to eliminate hepatitis C from the country - although it has had to drop a 2025 target

News

FDA approves first treatment for children with lupus

The US FDA has approved GSK’s Benlysta (belimumab) intravenous infusion for the treatment of children with lupus.

News

Illustration of a nerve cell on a colored background with light effects

Alder gears up for migraine showdown with eptinezumab filing

Alder BioPharmaceuticals has filed its migraine drug eptinezumab with the US regulator, the last in a gang of four CGRP-class antibodies developed to treat the condition.

News

NICE backs Akcea’s Tegsedi, pipping Alnylam to hATTR okay

NICE has recommended that Akcea’s hereditary transthyretin-related amyloidosis (hATTR) treatment Tegsedi be made available on the NHS in England, ahead of a rival therapy from Alnylam.

News

FDA approves PureTech's obesity device Plenity

The FDA has approved PureTech Health’s ‘space occupying’ device Plenity as a new prescription treatment for obesity, setting it up to rival Novo Nordisk in this lucrative market.

Sandoz strikes deal with EirGenix for Herceptin biosimilar

NHS trumpets Hep C deal, quietly drops 2025 elimination targ...

FDA approves first treatment for children with lupus

Alder gears up for migraine showdown with eptinezumab filing

NICE backs Akcea’s Tegsedi, pipping Alnylam to hATTR okay

FDA approves PureTech's obesity device Plenity

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks